尿路感染症に対するCefaclorの効果および酵素抗体法によるACBとの関連性

Abstract

1) 20例の尿路感染症に対し, 酵素抗体法によるACBの検出をおこなった.臨床的に診断された感染部位とACBとは, きわめてよく相関した.2) cefaclorの有効率は, 急性単純性膀胱炎80%, 急性腎盂腎炎100%, 複雑性尿路感染症60%であり, 尿路感染症全体では80%であった.3) cefaclorは, 臨床的に腎盂腎炎と診断され, しかもACB陽性の症例に対して100%の有効率を示した.これは臨床的に膀胱炎と診断され, しかもACB陰性の症例に対する有効率87.5%とほとんど差がなく, cefaclorは尿路感染症の治療薬として充分臨床効果が期待できる

Twenty out-patients suffering from urinary tract infections (UTI) were treated with cefaclor. Cefaclor was administrated orally in daily doses of 1, 500 mg for 7 days against 15 cases of simple UTI and 5 cases of complicated UTI. Of 20 cases with acute simple cystitis, acute pyelonephritis and complicated UTI, clinical responses were excellent in 10 cases, good in 6 cases and poor in 4 cases. The efficacy rate was 80%. No side effect was observed. The site of infection determined by the ACB detection method was in good agreement with that determined by clinical findings. Cefaclor appeared to be equally effective in the treatment of both ACB-positive and ACB-negative infections. The presence of absence of antibody-coated bacteria did not correlate with clinical symptoms or response to therapy.